Last Price
13.70
Today's Change
+0.12 (0.88%)
Day's Change
13.42 - 13.76
Trading Volume
54,819
Exchange: Australian Securities Exchange Australian Securities Exchange
Currency: AUD AUD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Philippe Jacques Wolgen M.B.A., M.D. Dr. Philippe Jacques Wolgen M.B.A., M.D.
Full Time Employees: 16 16
IPO Date: 2001-02-11 2001-02-11
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49